About 3,653 results

ALLMedicine™ Calcitonin Gene-related Peptide Center

Research & Reviews  1,302 results

Diurnal changes of colonic motility and regulatory factors for colonic motility in Sunc...
Neurogastroenterology and Motility : the Official Journal... Kobayashi Y, Takemi S et. al.

Dec 1st, 2021 - The aim of this study was to investigate the fundamental mechanisms of colonic motility in the house musk suncus (Suncus murinus) as an established animal model of gut motility. To measure gut motility in free-moving conscious suncus, strain gauge...

PACAP38- and VIP-induced cluster headache attacks are not associated with changes of pl...
Cephalalgia : an International Journal of Headache; Pellesi L, Chaudhry BA et. al.

Nov 26th, 2021 - Pituitary adenylate cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide can provoke cluster headache attacks in up to half of cluster headache patients in their active phase. At present, it is unknown whether provoked...

Atogepant: First Approval.
https://doi.org/10.1007/s40265-021-01644-5 10.1038/s41582-021-00509-5 10.1016/j.pharmthera.2020.107528 10.1007/s40263-019-00665-9 10.1177/0333102419884943 10.1177/0333102420970507 10.1002/cpdd.940 10.1111/cts.12917 10.1002/cpdd.916 10.1007/s40261-021-01034-5 10.1002/jcph.1610 10.1056/NEJMoa2035908 10.1177/03331024211042385 10.1016/S1474-4422(20)30234-9
Drugs Deeks ED

Nov 24th, 2021 - Atogepant (Qulipta™) is an orally administered, small-molecule, calcitonin gene-related peptide (CGRP) receptor antagonist being developed by AbbVie for the prophylaxis of migraine. In September 2021, atogepant was approved in the USA for the prev...

Evaluation of the Pharmacokinetic Interaction and Safety of Ubrogepant Coadministered W...
Clinical Pharmacology in Drug Development; Boinpally R, Lu K

Nov 24th, 2021 - Ubrogepant is a calcitonin gene-related peptide receptor antagonist for the acute treatment of migraine. Esomeprazole magnesium increases intragastric pH, which may affect oral ubrogepant absorption. This open-label, nonrandomized, crossover trial...

see more →

Guidelines  1 results

European headache federation guideline on the use of monoclonal antibodies acting on th...
The Journal of Headache and Pain; Sacco S, Bendtsen L et. al.

Jan 18th, 2019 - Monoclonal antibodies acting on the calcitonin gene-related peptide or on its receptor are new drugs to prevent migraine. Four monoclonal antibodies have been developed: one targeting the calcitonin gene-related peptide receptor (erenumab) and thr...

see more →

Drugs  6 results see all →

Clinicaltrials.gov  16 results

A Controlled Trial of Erenumab in Migraine Prevention

Nov 16th, 2021 - Migraine prevention is an area of a large unmet medical need, with existing therapies often having modest efficacy and poor tolerability. Calcitonin gene-related peptide (CGRP) receptor antagonism is a novel approach to migraine preventive therapy...

The Effects of Levcromakalim in Patients With Cluster Headache

Oct 26th, 2021 - Cluster headache is a primary headache disorder characterized by attacks of unilateral headache of short duration and severe pain intensity. There is an unmet need to understand the underlying disease mechanisms that will ultimately lead to the de...

Neuropeptides and Venous Pelvic Pain

Sep 21st, 2021 - The first phase of the study includes a set of 3 patient groups: the first is patients with pelvic vein dilation and blood reflux through them in combination with venous pelvic pain; the second is patients with pelvic vein dilatation without venou...

Management of Migraine Using Enerumab and Traditional Therapy at the Time of COVID-19

Sep 21st, 2021 - Migraine is a debilitating disorder that affects 37 million people in the United States. Recently, three new injectables calcitonin gene-related peptide (CGRP) receptor antagonists-erenumab, fremanezumab, and galcanezumab-were FDA approved for pro...

Cardiovascular Protection Conservative Effects of Esketamine Versus µ-opioid Receptor Agonists in General Anesthesia

Mar 17th, 2021 - Pain has two sides. The 'bad pain' refers to the adverse impact of pain on humans, which disturbs daily life of the sufferers. Evidence indicates that in the transduction and transmission of the painful signals some molecules may retrogradely movi...

see more →

News  136 results

Atogepant Reduces Migraine Days: ADVANCE Trial Published

Aug 25th, 2021 - The novel calcitonin gene-related peptide (CGRP) antagonist atogepant is safe and effective for the preventive treatment of migraine, full results from a phase 3 trial suggest. AbbVie, the company developing the oral therapy, announced topline res...

AHS Releases Updated Guidance on New Migraine Treatments

Jul 16th, 2021 - An updated consensus statement from the American Headache Society (AHS) offers detailed recommendations on the use of novel acute and preventive treatments in adult patients with migraine. "Because the benefit–risk profiles of newer treatments wil...

Updated consensus statement assesses new migraine treatments
Steve Cimino

Jul 15th, 2021 - An updated consensus statement from the American Headache Society (AHS) offers detailed recommendations on the use of novel acute and preventive treatments in adult patients with migraine. “Because the benefit–risk profiles of newer treatments wil.

New Migraine Treatments: Which Is Right for Your Patients?

Jul 2nd, 2021 - It's an exciting time to be treating people with migraine. The past several years have seen a profusion of new migraine treatment options, and clinicians have more choices to offer patients than ever. In addition to acute and preventive therapies ...

Migraine Linked to More COVID-19 Infections, Symptoms

Jun 15th, 2021 - Editor's note: Find the latest COVID-19 news and guidance in Medscape's Coronavirus Resource Center. Dr Robert Shapiro People with migraines appeared to have a higher likelihood of COVID-19 infection and subsequent symptoms of the disease, but the...

see more →